Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation

被引：23
|
作者：
Ru, Yuhua [1 ,2 ]
Chen, Jia [1 ,2 ]
Wu, Depei [1 ,2 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou 215006, Peoples R China
[2] Soochow Univ, Collaborat Innovat Ctr Hematol, Inst Blood & Marrow Transplantat, Suzhou 215006, Peoples R China
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2018年 / 101卷 / 03期
基金：
美国国家科学基金会; 国家重点研发计划;
关键词：
EB virus; hematopoietic stem cell transplantation; lymphoproliferative disease; BONE-MARROW-TRANSPLANTATION; EBV REACTIVATION; RISK-FACTORS; VIRAL LOAD; PREEMPTIVE RITUXIMAB; PROLONGED HYPOGAMMAGLOBULINEMIA; ALLOGENEIC TRANSPLANTATION; HEART-TRANSPLANTATION; EUROPEAN CONFERENCE; PEDIATRIC-PATIENTS;
D O I：
10.1111/ejh.13131
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Epstein-Barr virus (EBV) viremia and post-transplant lymphoproliferative disease (PTLD) are severe complications after hematopoietic stem cell transplantation (HSCT). A series of risk factors have been found to predict EBV viremia and PTLD, including the T-cell depletion, reduced intensity conditioning, and alternative donor. The rituximab pre-emptive therapy could improve PTLD prognosis significantly, but the trigger of initiating rituximab pre-emptive therapy has not been well established. Additionally, EBV-specific cytotoxic T cell (CTL) is a promising approach to treat EBV-PTLD.
引用
收藏
页码：283 / 290
页数：8
相关论文
共 50 条
  • [31] Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
    Styczynski, Jan
    van der Velden, Walter
    Fox, Christopher P.
    Engelhard, Dan
    de la Camara, Rafael
    Cordonnier, Catherine
    Ljungman, Per
    HAEMATOLOGICA, 2016, 101 (07) : 803 - 811
  • [32] Late Epstein-Barr virus-related post-transplant lymphoproliferative disorder with intestinal involvement in patient with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Hjellbakk, Hedda Kloster
    Adamska, Monika Malgorzata
    Malecki, Bartosz
    Brzezniakiewicz-Janus, Katarzyna
    Lojko-Dankowska, Anna
    Gil, Lidia
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2020, 45 (02) : 233 - 236
  • [33] Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation
    Pagliuca, Simona
    Bommier, Come
    Michonneau, David
    Meignin, Veronique
    Salmona, Maud
    Robins, Marie
    Prata, Pedro Henrique
    Xhaard, Alienor
    de Fontbrune, Flore Sicre
    Feghoul, Linda
    Dhedin, Nathalie
    de Latour, Regis Peffault
    Caillat-Zucman, Sophie
    Le Goff, Jerome
    Socie, Gerard
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (12) : 2490 - 2500
  • [34] NK-cell post-transplant lymphoproliferative disease successfully treated by second allogenic hematopoietic stem cell transplantation in chronic active Epstein–Barr virus infection
    Sho Shibata
    Yoko Takiuchi
    Naoto Kawasaki
    Yoshio Okamoto
    Shojiro Inano
    Akiko Fukunaga
    Sumie Tabata
    Ayako Arai
    Ken-Ichi Imadome
    Toshiyuki Kitano
    International Journal of Hematology, 2022, 115 : 595 - 599
  • [35] The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation
    Sundin, Mikael
    Le Blanc, Katarina
    Ringden, Olle
    Barkholt, Lisbeth
    Omazic, Brigitta
    Lergin, Christina
    Levitsky, Victor
    Remberger, Mats
    HAEMATOLOGICA, 2006, 91 (08) : 1059 - 1067
  • [36] Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment
    Chiereghin, A.
    Prete, A.
    Belotti, T.
    Gibertoni, D.
    Piccirilli, G.
    Gabrielli, L.
    Pession, A.
    Lazzarotto, T.
    TRANSPLANT INFECTIOUS DISEASE, 2016, 18 (01) : 44 - 54
  • [37] Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation
    Gruhn, B
    Meerbach, A
    Häfer, R
    Zell, R
    Wutzler, P
    Zintl, F
    BONE MARROW TRANSPLANTATION, 2003, 31 (11) : 1023 - 1025
  • [38] Automated quantification of Epstein-Barr virus in whole blood for post-transplant lymphoproliferative disorders monitoring
    Salmona, Maud
    Stefic, Karl
    Mahjoub, Nadia
    de Fontbrune, Flore Sicre
    Maylin, Sarah
    Simon, Francois
    Scieux, Catherine
    Socie, Gerard
    Mazeron, Marie-Christine
    LeGoff, Jerome
    VIROLOGY JOURNAL, 2020, 17 (01)
  • [39] Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders
    Dolores Fellner, Maria
    Durand, Karina A.
    Solernou, Veronica
    Bosaleh, Andrea
    Balbarrey, Ziomara
    Garcia de Davila, Maria T.
    Rodriguez, Marcelo
    Irazu, Lucia
    Alonio, Lidia V.
    Picconi, Maria A.
    REVISTA ARGENTINA DE MICROBIOLOGIA, 2016, 48 (02): : 110 - 118
  • [40] Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients
    Baldanti, Fausto
    Rognoni, Vanina
    Cascina, Alessandro
    Oggionni, Tiberio
    Tinelli, Carmine
    Meloni, Federica
    VIROLOGY JOURNAL, 2011, 8
12345